(Q36773479)

16 August 2017

1 reference

title

Obesity pharmacotherapy from a regulatory perspective: overview and key challenges (English)

1 reference

16 August 2017

0 references

Hutchinson NI

1

1 reference

16 August 2017

Ryder SW

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

28 March 2007

1 reference

Clinical Pharmacology & Therapeutics

16 August 2017

published in

1 reference

16 August 2017

volume

81

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

756-760

1 reference

Mortality and weight: insured lives and the American Cancer Society studies

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

Prevalence of overweight and obesity in the United States, 1999-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Mortality of severely obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

The effect of age on the association between body-mass index and mortality.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Pharmacotherapy for obesity--promise and uncertainty

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Randomized trial of lifestyle modification and pharmacotherapy for obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

The definition of weight maintenance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

1 reference

7 January 2021

Obesity and pharmacologic therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Primary pulmonary hypertension and fenfluramine use

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100169

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100169

1 reference

release_oqwl7ik6kjbczgb3uw76w65tti

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oqwl7ik6kjbczgb3uw76w65tti

24 November 2022

mapped directly with Wikidata item

1 reference